News and Events, Recent News

FDA Approves the Roll-Over Combination Study with Checkpoint Inhibitor Immunotherapies to Allow Continued Access to their Immunotherapy in Patients with Advanced Breast Cancer

BERKELEY, Calif. and VANCOUVER, British Columbia, Oct 30, 2017 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, announced today that the FDA has approved the roll-over combination study of BriaVax™ with pembrolizumab {Keytruda; manufactured by Merck & Co., Inc. (NYSE: MRK)} […]

Recent News

BriaCell Announces Warrant Incentive Program

Berkeley, CA and Vancouver, BC – October 13, 2017 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company“) (TSXV: BCT) (OTCQB: BCTXF) announced today that it is introducing a warrant exercise incentive program (the “Incentive Program“) designed to encourage the early exercise of up to approximately 26 million outstanding common share purchase warrants (the “Warrants “). […]

Recent News

BriaCell Announces Repricing of Warrants

Berkeley, CA and Vancouver, BC – October 3, 2017 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF) announced today that it is applying to the TSX Venture Exchange (the “Exchange”) for approval to amend the terms of an aggregate of 1,562,500 common share purchase warrants (the “Warrants”) issued pursuant to a […]